Overview

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

Status:
Completed

Trial end date:
2017-05-31

Target enrollment:

Participant gender:

Summary

Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Carmustine
Cytarabine
Etoposide
Etoposide phosphate
Melphalan